Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of CSL312 (Garadacimab) in Healthy Japanese and Caucasian Adults
NCT04580654Phase 1Completed
- Sponsor
- CSL Limited
- Start
- Oct 2020
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of garadacimab in hereditary angioedema (HAE) (5 cohorts), sponsored by CSL Limited. Primary endpoints: Maximum plasma concentration of CSL312 after subcutaneous dosing and Area under the curve from time 0 extrapolated to infinity of CSL312 after subcutaneous dosing. Started Oct 2020; status: completed.
02
Drugs
garadacimab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT04580654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04580654.